COVID-19 Research Paper Volume 12, Issue 20 pp 19923—19937

Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions


Figure 1. Relative Risk (RR) with 95% Confidence Interval (CI95%) of COVID-19 diagnosis according to the exposure to different treatments, adjusted by sex, age, CV disease, diabetes, pulmonary disease, chronic kidney disease and active cancer or treatments. The effect of Denosumab Zoledronate, Calcium, Oral bisphosphonates and Vitamin D were obtained from Model 1. Estimates for Duloxetine, SSRIs, Gabapentin, Pregabalin, ACE inhibitors and ARBs were obtained from Model 2.